Jackson Creek Investment Advisors LLC Acquires 114 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Jackson Creek Investment Advisors LLC grew its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,742 shares of the biotechnology company’s stock after buying an additional 114 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in United Therapeutics were worth $967,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics during the 4th quarter valued at $25,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in shares of United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB lifted its stake in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its holdings in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $315.91 on Friday. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The business has a fifty day moving average price of $355.41 and a two-hundred day moving average price of $360.08. The stock has a market capitalization of $14.19 billion, a PE ratio of 13.87, a P/E/G ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the business posted $4.36 EPS. On average, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity

In other news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,464 shares of company stock worth $42,396,244. Corporate insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.